BRCA2 and breast carcinoma: Indeed, PARP1 inhibitors are currently one of the most promising therapeutic agents for several cancers, especially breast cancer, and can selectively target tumor cells with BRCA1 or BRCA2 tumor suppressor gene mutations through synthetic lethality [33, 34].